Viking Therapeutics is a pre-revenue biotech with a cash-burning profile, four consecutive earnings misses averaging minus 39%, confirmed price downtrend, and quality metrics below the minimum investment threshold, though analysts maintain an average price target more than 200% above the current level reflecting pipeline optionality.
Thesis pillars
- Analyst Price Target Divergence→Stable
- Four Consecutive Earnings Misses↓Deteriorating
- Below Quality Floor Cash Burn↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 11, 2026· older than 90 days
Viking Therapeutics, Inc. (VKTX) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend.
Viking Therapeutics is a pre-revenue clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, with lead asset VK2735 (GLP-1/GIP dual agonist for obesity) in Phase 3 VANQUISH studies and a Phase 2 oral formulation completed in August... Read more
Sell if holding. Engine safety override at $26.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Score 4.3/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 95d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Viking Therapeutics, Inc.
About Viking Therapeutics, Inc.
Viking Therapeutics enrolled the VANQUISH-1 Phase 3 obesity study in November 2025 and initiated the companion VANQUISH-2 study — both evaluating subcutaneous VK2735, a GLP-1/GIP dual agonist that produced up to 14.7% body weight reduction in the Phase 2 VENTURE trial. The oral tablet formulation of VK2735 achieved up to 12.2% body weight loss in Phase 2 results announced August 2025. With an accumulated deficit of $847.5 million at December 31, 2025, Viking held $705.7 million in cash, cash equivalents, and investments.
Viking Therapeutics generates no commercial revenue and funds operations through equity offerings; the March 2024 underwritten offering raised $597.1 million in net proceeds at $85.00 per share for 7,441,650 shares. The pipeline spans VK2735 subcutaneous (Phase 3, VANQUISH program, 78-week trials), VK2735 oral (Phase 2 complete; Phase 3 initiation targeted Q3 2026), VK2809 (Phase 2b positive MASH/NASH data, including up to 75% NASH resolution at 52 weeks versus 29% for placebo), and VK0214 (Phase 1b complete in X-linked adrenoleukodystrophy). In March 2025, the company secured manufacturing agreements with Corden Pharma Colorado covering API and final finished product for VK2735 — including dedicated capacity for multiple metric tons of API annually, 100 million autoinjectors per year, and over one billion oral tablets per year. Technology underlying VK2809, VK0214, VK5211, and VK0612 is licensed from Ligand Pharmaceuticals under the Master License Agreement, which grants Ligand termination rights in the event of Viking's insolvency or failure to cure a material obligation default.
Show full overview
Viking Therapeutics' near-term valuation is anchored to the VANQUISH Phase 3 readout for subcutaneous VK2735 — the only program at the Phase 3 stage in the pipeline at December 31, 2025. If the VANQUISH studies fail to replicate Phase 2 efficacy or reveal unexpected safety signals, the company's ability to raise the additional capital it acknowledges needing could be significantly impaired, given that it has never generated revenue and carried an $847.5 million accumulated deficit. Separately, the Ligand Master License Agreement covers VK2809, VK0214, VK5211, and VK0612; its termination would remove most of the secondary pipeline simultaneously.
See also: Healthcare · Biotechnology
From Viking Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Oct 31, 2026Recent Developments — Viking Therapeutics, Inc.
Latest news
- NEWS Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118 — benzinga Oct 31, 2026 positive
- NEWS Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress — fiscal.ai Oct 30, 2026
- NEWS CORRECTION: Viking Therapeutics Ticker Is "VKTX" Not "VIK" — benzinga Oct 29, 2026 neutral
- NEWS Viking Therapeutics Stock Jumps: What's Going On? — benzinga Oct 29, 2026 positive
- NEWS Viking Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai Oct 28, 2026
Latest item Oct 31, 2026 · Generated 2026-11-07T12:07:53Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineVK2735 subcutaneous10-K Item 1A: 'VK2735 subcutaneous, which is in Phase 3 development'
- HIGHSupplierCordenPharma10-K Item 1: 'Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735'
- HIGHcounterpartyLigand Pharmaceuticals10-K Item 1A: 'Our business is substantially dependent upon technology licensed from Ligand'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $24.96. Score 4.3/10, moderate confidence.
Resistance target: $28.26 (+5.3% upside). Prior stop was $24.96. Stop-loss: $24.96.
Concentration risk — Supplier: CordenPharma; Concentration risk — Counterparty: Ligand Pharmaceuticals; DATA_ISSUE: analyst_target_implausible (raw $95.32 vs price $26.84 — ratio 3.6×). Rejected, falling back to technical TP..
Viking Therapeutics, Inc. trades at a P/E of N/A (forward -5.2). TrendMatrix value score: 5.0/10. Verdict: Sell.
27 analysts rate VKTX, with a consensus score of 4.2/5. 19 analysts publish price targets averaging $95.
What does Viking Therapeutics, Inc. do?Viking Therapeutics is a pre-revenue clinical-stage biopharmaceutical company developing therapies for metabolic and...
Viking Therapeutics is a pre-revenue clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, with lead asset VK2735 (GLP-1/GIP dual agonist for obesity) in Phase 3 VANQUISH studies and a Phase 2 oral formulation completed in August 2025. The company had an accumulated deficit of $847.5 million through December 31, 2025, with $705.7 million in cash, cash equivalents, and investments.